诺华制药拟10亿美元扩建中国研发中心

　　Novartis yesterday revealed plans to invest $1bn to expand its Shanghai laboratories and make China the third pillar of its global research and development capabilities.
　　诺华制药(Novartis)昨日宣布，计划投资10亿美元扩建在上海的实验室，使中国成为其全球研发能力的第三大支柱。

　　Daniel Vasella, chairman, said the Swiss drugs group would build a new campus in Shanghai to house its research activities, which would employ 1,000 scientists in five years' time.
　　诺华制药董事长魏思乐(Daniel Vasella)表示，这家瑞士制药集团将在上海建立一座新的研发基地，该基地将在5年里达到1000名科研人员的规模。

　　The announcement is the latest sign that major pharmaceuticals groups are eager to tap China's growing scientific base and demonstrates how emerging economies have become central to their plans as markets in the US and Europe struggle.
　　此项宣布是一个最新迹象，表明大型制药集团迫切希望利用中国日益壮大的科研基地，同时展示，在美国与欧洲市场举步维艰之际，新兴经济体已在它们的计划中占据中心地位。

　　The move comes after significant investments in recent years by several big western companies, including AstraZeneca, Roche and GlaxoSmithKline, seeking to recruit local expertise, take advantage of lower costs and expand their presence in one of the world's fastest-growing drugs markets.
　　近几年来，包括阿斯利康(AstraZeneca)、罗氏(Roche)及葛兰素史克(GlaxoSmithKline)在内的不少西方大公司在中国进行了大手笔的投资，试图吸纳本土人才，利用成本降低的优势，并在全球增长最快的药品市场之一扩大自己的地盘。

　　Mr Vasella said the group's China business had lifted revenues by 30 per cent a year over the past five years to become one of its top 10 markets. He predicted China would be one of its top three markets after another five years.
　　魏思乐表示，过去5年来，该集团的中国业务收入每年增长30%，中国已成为它的前十大市场之一。他预测，再过5年，中国将跻身该公司的前三大市场。

　　China's plans to invest Rmb850bn ($124.5bn) in healthcare reform over the next three years would maintain high rates of growth in spending on medicines. “Healthcare reform in China means more growth in our operations, while in other countries it means less,” said Mr Vasella.
　　中国在未来3年里为医疗改革投入8500亿元人民币（1245亿美元）的计划，将维持药品支出的高增长率。魏思乐表示：“中国的医改意味着我们的业务将获得更多增长，而在其它国家，情况恰恰相反。”

　　Novartis moved its research base from Basel to Cambridge, Massachusetts, in 2004. Mr Vasella said the experience in Cambridge “taught us that you have to go where the talent is rather than getting the talent to come to where we are”.
　　诺华制药于2004年把研发基地从巴塞尔迁至美国马萨诸塞州的剑桥。魏思乐表示，在剑桥的经历“告诉我们，你必须去人才所在的地方，而不是让人才自己送上门。”

　　He said it would be no problem to hire qualified people for the expanded Shanghai facility, which will mix Chinese nationals who have experience overseas with recent graduates. “It is much easier now to invite people to go back to Shanghai,” said Mr Vasella.
　　他表示，上海实验室扩建后，招聘合格人才将不成问题，该实验室将聘用一部分海归中国籍人士，以及一部分近年的毕业生。“如今邀请人们回上海工作，要比过去容易得多，”魏思乐表示。

　　Novartis set up its Shanghai research facilities in 2006 with a $100m investment. After focusing on the infectious causes of cancer, Mr Vasella said the expanded R&D operation would focus on cardiovascular diseases and collaborate on some projects with Basel and Cambridge.
　　诺华制药于2006年投资1亿美元在上海建立了研发中心，重点研究导致癌症的感染因素。魏思乐表示，扩张后的研发业务，将聚焦于心血管疾病，并将在一些项目上与巴塞尔及剑桥方面展开合作。

　　The group also unveiled a $250m investment in a facility to develop and manufacture raw materials used in medicines. The plant will be in Changshu in China's Jiangsu province.
　　该集团还宣布，将投资2.5亿美元，在江苏省常熟市建立一家开发和制造药品原材料的工厂。
　　
　　译者/章晴